Zobrazeno 1 - 10
of 15
pro vyhledávání: '"James N. Atkins"'
Autor:
Everett E. Vokes, Herbert Pang, Rafat Ansari, Lydia Hodgson, Jeffrey A. Bogart, Mark R. Green, James N. Atkins, Michael J. Kelley
Publikováno v:
Journal of Thoracic Oncology. 8:102-108
Introduction: We sought to determine the efficacy of using both irinotecan- and etoposide-containing regimens sequentially for patients with untreated limited-stage small-cell lung cancer. Methods: Patients with untreated, measurable, limited-stage s
Autor:
Mark R. Green, Harvey B. Niell, Everett E. Vokes, James E. Herndon, Michael J. Kelley, Lydia Hodgson, Nithya Ramnath, Wallace Akerley, M. Giulia Cicchetti, Thomas E. Stinchcombe, James N. Atkins
Publikováno v:
Journal of Thoracic Oncology. 4(9):1117-1125
BackgroundIn Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved survival and demonstrated no significant benefit from the addition of induction chemotherapy. The
Autor:
J. Wendall Goodwin, James D. Bearden, David R. Gandara, Kari Chansky, Jason McCoy, Wallace Akerley, James N. Atkins, John Crowley, Paul J. Hesketh
Publikováno v:
Journal of Thoracic Oncology. 2(6):526-530
Introduction To evaluate the activity of a nonplatinum-, nonetoposide-containing regimen for patients with extensive stage small cell lung cancer. Methods Patients with untreated extensive stage small cell lung cancer were treated with gemcitabine 10
Autor:
Dorothy Watson, Nithya Ramnath, Everett E. Vokes, Mark R. Green, Wallace Akerley, M. Giulia Cicchetti, James E. Herndon, Harvey Neill, Michael J. Kelley, James N. Atkins
Publikováno v:
Journal of Clinical Oncology. 25:1698-1704
Purpose Standard therapy for unresectable stage III non–small-cell lung cancer includes concomitant chemoradiotherapy. In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would resul
Autor:
Mark R. Green, Sara J Grethein, Daniel C Ihde, Everett E. Vokes, Michael L. Grossbard, James N. Atkins, James E. Herndon, Michael C. Perry
Publikováno v:
Lung Cancer. 28:63-68
In order to explore non-cisplatin containing regimens for advanced non-small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimen
Autor:
Kari Chansky, Karen Kelly, James N. Atkins, David R. Gandara, Kathy S. Albain, Wilbur A. Franklin, John Crowley, Edward S. Kim, Roy S. Herbst, Shaker R. Dakhil, Fred R. Hirsch, Philip C. Mack, Mary W. Redman
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(31)
Purpose Randomized clinical trials failed to show a survival benefit for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors plus concurrent chemotherapy in patients with metastatic non–small-cell lung cancer (NSCLC), with preclinica
Autor:
James N. Atkins, R Burgess, Giorgio V. Scagliotti, L. Tye, Julie R. Brahmer, Silvia Novello, Cinta Pallares, E Wang, Ramaswamy Govindan, Paulina Selaru, Richard C. Chao, Rafael Rosell, Mark A. Socinski
Publikováno v:
BRITISH JOURNAL OF CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
British Journal of Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
British Journal of Cancer
BACKGROUND: Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 ( 4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC). METHODS: We examined the activity of sunitinib o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ce1d4b01babc5d8f886c029ef318dd7
http://hdl.handle.net/2318/65476
http://hdl.handle.net/2318/65476
Autor:
Mark A. Socinski, Ramaswamy Govindan, Julie R. Brahmer, L. Tye, Jose Miguel Sanchez, Giorgio V. Scagliotti, Heidi H. Gillenwater, Paulina Selaru, Chandra P. Belani, Rafael Rosell, Silvia Novello, James N. Atkins, Richard C. Chao, Cinta Pallares
Purpose Aberrant vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) signaling have been shown to play a role in non–small-cell lung cancer (NSCLC) pathogenesis and are associated with decreased survival. We evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c25805a2b3790c0694efd980905f3e40
http://hdl.handle.net/2318/27770
http://hdl.handle.net/2318/27770
Autor:
Paul J, Hesketh, Jason, McCoy, Frank R, Dunphy, James D, Bearden, Geoffrey R, Weiss, Jeffrey K, Giguere, James N, Atkins, Shaker R, Dakhil, Karen, Kelly, John J, Crowley, David R, Gandara
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 1(9)
This phase II study (S9914) evaluated the efficacy and toxicity of the three-drug combination of paclitaxel, carboplatin, and topotecan with granulocyte colony-stimulating factor support in previously untreated patients with extensive stage small cel
Autor:
Primo N, Lara, Kari, Chansky, Angela M, Davies, Wilbur A, Franklin, Paul H, Gumerlock, Perry P, Guaglianone, James N, Atkins, Nichole, Farneth, Philip C, Mack, John J, Crowley, David R, Gandara
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 1(9)
In preclinical models, the proteasome inhibitor bortezomib (PS-341) inhibits the growth of small cell lung cancer (SCLC) by inhibiting the antiapoptotic Bcl-2 signaling pathway. We conducted a phase II trial of PS-341 in previously treated patients w